Nzyme Close €160 Million Fund From Kibo Ventures

Nzyme takes a careful, hands-on approach, backing well-run companies with strong foundations—many of which are located outside major cities. It supports them in scaling, professionalizing, and integrating technology to grow faster and smarter.

The fund helps businesses tackle one of the toughest growth challenges: moving from teams of 20–40 people to structured organizations of 150+ with scalable systems, tech integration, and global ambitions.

Read Also - German Fintech re:cap Raises €125M Credit Facility and Expands Into UK Market

Nzyme focuses on companies with at least €1 million EBITDA or around 20 employees, aiming to build 8–10 sector platforms. Each platform will receive €15–20 million, using a buy-and-build strategy to combine multiple businesses. The fund’s growth approach includes advanced tech like AI, big data, IoT, cloud and machine learning to boost efficiency and competitiveness.

So far, Nzyme has invested in healthcare distribution through the Kuma Group and several professional services firms. In April 2025, it exited Kuma’s dental division—less than two years after acquiring it.

The fund is led by a seasoned team—Fernando Díaz Solís, Vicente Vázquez Bouza, José Manuel Gasalla, Juan López Santamaría, and Pablo Campos—and supported by Oliver Wyman as a strategic advisor.

Investors include CDTI (via SICC Innvierte), leading Spanish business families, successful entrepreneurs, banks, and international family offices. According to Vicente Vázquez, the fund’s success despite a tough market reflects strong investor trust in Nzyme’s team, strategy, and the growth potential of Spanish SMEs.

“We are convinced that by combining business consolidation with technological innovation, we can create strong leaders in traditional and fragmented sectors.

We remain committed to generating sustainable value and contributing to the country’s economic development through strategic investments and a close, hands-on approach with the companies.”

About Nzyme

Nzyme is a private equity fund that helps strong teams grow and innovate. Like enzymes in biology, it speeds up transformation by supporting business integration and building market-leading companies.